Takeda Pharmaceutical Co Ltd - Company Profile
Powered by
All the data and insights you need on Takeda Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Takeda Pharmaceutical Co Ltd Strategy Report
- Understand Takeda Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Takeda Pharmaceutical Co Ltd patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
EP4058430A1 | Application | HETEROZYKLISCHE NMDA-ANTAGONISTEN | A61K31/4015; A61K31/4439; A61K31/497; A61K31/506; A61P25/06; A61P25/18; A61P25/24; A61P25/28; C07D207/263; C07D263/22; C07D401/06; C07D403/06; C07D413/06 | September 21, 2022 |
EP2817334B1 | Grant | FRAKTION I-IV-1 FÄLLUNG VON IMMUNOGLOBULINEN AUS PLASMA | A61K35/16; A61K39/395; A61K39/39591; A61P27/02; A61P29/00; A61P31/00; A61P37/00; A61P37/02; C07K1/145; C07K1/30; C07K16/065 | September 21, 2022 |
EP3904374A4 | Search Report | T-ZELL-REZEPTOR-MODIFIZIERTES OBJEKT | C07K14/705; C07K14/7051; C07K2319/00; C07K2319/02; C12N15/63; C12N15/86; C12N2510/00; C12N2740/15043; C12N2740/16043; C12N5/0636 | September 21, 2022 |
EP3888693A4 | Search Report | WIRKSTOFFFREISETZUNGSSYSTEM MIT VERWENDUNG EINER LÖSUNG | A01K2207/15; A01K2217/072; A01K2217/075; A61K31/7088; A61K38/465; A61K47/10; A61K47/12; A61K47/16; A61K47/18; A61K47/183; A61K47/22; A61K47/24; A61K47/26; A61K48/00; A61K9/08; C12N15/113; C12N15/87; C12N15/90; C12N2310/20; C12N9/22 | September 21, 2022 |
AU2021249040A1 | Application | A method to produce an immunoglobulin preparation from C-1 inhibitor depleted plasma | A61K2039/505; C07K16/06; C07K16/065; C07K16/18; C07K2317/10 | September 15, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer